Abstract
Background and Aim
Severe acute hepatitis B is a rapid deterioration of liver function, which carries a high mortality rate. The aim of this study is to evaluate the efficacy of lamivudine in patients with severe acute hepatitis B.
Methods
In this study, 80 patients with severe acute hepatitis B were randomly divided into lamivudine and the control group. For the two groups, we compared HBsAg, HBeAg seroconversion rates, serum HBV DNA-negative rate, biochemical indicators, the incidence of liver failure, and mortality. The influential factors on the mortality were studied by Cox proportional hazards model.
Results
The improvement in serum TBiL, INR, and HBV DNA levels of the lamivudine group was significantly greater than that of the control group. The mortality of lamivudine group (7.5%, 3/40) was significantly lower than that of the control group (25.0%, 10/40) (p = 0.034). The incidence of liver failure (8.7%, 2/23) of patients receiving lamivudine within a week was significantly lower than that (35.3%, 6/17) of those who received it after a week (p = 0.038). In multivariate Cox proportional hazards analyses, age (p = 0.043), ratio of total to direct bilirubin (p = 0.009), treatment method (p = 0.006), and the decline of HBV DNA load during therapy (p = 0.017) were independent predictors of mortality. The HBsAg seroconversion rates (62.5%, 25/40) and HBeAg seroconversion rates (63.6%, 21/33) of the lamivudine group were significantly lower than those (85.0%, 34/40), (87.5%, 28/32) of the control group (p = 0.022, 0.026).
Conclusions
Early treatment with lamivudine leads to a greater decrease in HBV DNA level, better clinical improvement and mortality improvement in patients with severe acute hepatitis B, but with a lower seroconversion rate. A rapid decline of HBV DNA load is a good predictor for the treatment outcome.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ostapowicz G, Fontana RJ, Schiodt FV, et al. U.S. Acute Liver Failure Study Group. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med. 2002;137:947–954.
Chien RN, Lin CH, Liaw YF. The effect of lamivudine therapy in hepatic decompensation during acute exacerbation of chronic hepatitis B. J Hepatol. 2003;38:322–327.
Hoofnagle JH, Doo E, Liang TJ, Fleischer R, Lok AS. Management of hepatitis B: Summary of a clinical research workshop. Hepatology. 2007;45:1056–1075.
Reshef R, Sbait W, Tur-Kaspa R. Lamivudine in the treatment of acute hepatitis B. N Engl J Med. 2000;343:1123–1124.
Torii N, Hasegawa K, Ogawa M, et al. Effectiveness and long-term outcome of lamivudine therapy for acute hepatitis B. Hepatol Res. 2002;24:34–41.
Roznovsky L, Orságová I, Kloudová A, et al. Lamivudine therapy in patients with severe acute hepatitis B. Klin Mikrobiol Infekc Lek. 2007;13:59–65.
Tillmann HL, Hadem J, Leifeld L, et al. Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience. J Viral Hepat. 2006;13:256–263.
Lisotti A, Azzaroli F, Buonfiglioli F, et al. Lamivudine treatment for severe acute HBV hepatitis. Int J Med Sci. 2008;5:309–312.
Kumar M, Satapathy S, Monga R, et al. A randomized controlled trial of lamivudine to treat acute hepatitis B. Hepatology. 2007;45:97–101.
Sainokami S, Abe K, Sato A, et al. Initial load of hepatitis B virus (HBV), its changing profile, and precore/core promoter mutations correlate with the severity and outcome of acute HBV infection. J Gastroenterol. 2007;42:241–249.
O’Grady JG, Alexander GJ, Hayllar KM, Williams R. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology. 1989;97:439–455.
Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association and Severe Liver Diseases and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association. Diagnostic and treatment guidelines for liver failure. Zhonghua Gan Zang Bing Za Zhi. 2006;14:643–646.
Sterneck M, Gunther S, Santantonio T, et al. Hepatitis B virus genomes of patients with fulminant hepatitis do not share a specific mutation. Hepatology. 1996;24:300–306.
Schmilovitz-Weiss H, Ben-Ari Z, Sikuler E, et al. Lamivudine treatment for acute severe hepatitis B: A pilot study. Liver Int. 2004;24:547–551.
Dhiman RK, Seth AK, Jain S, Chawla YK, Dilawari JB. Prognostic evaluation of early indicators in fulminant hepatic failure by multivariate analysis. Dig Dis Sci. 1998;43:1311–1316.
Miyake Y, Iwasaki Y, Takaki A, et al. Lamivudine treatment improves the prognosis of fulminant hepatitis B. Inter Med. 2008;47:1293–1299.
Yu JW, Wang GQ, Zhao YH, Sun LJ, Wang SQ, Li SC. The MELD scoring system for predicting prognosis in patients with severe hepatitis after plasma exchange treatment. Hepatobiliary Pancreat Dis Int. 2007;6:492–496.
Yu JW, Sun LJ, Zhao YH, et al. Prediction value of MELD scoring system on prognosis in patients with acute-on-chronic hepatitis B liver failure after plasma exchange and lamivudine treatment. J Gastroenterol Hepatol. 2008;23:1242–1249.
Bocher WO, Herzog-Hauff S, Herr W, et al. Regulation the neutralizing anti-hepatitis B surface (HBS) antibody response in vitro in HBs vaccine recipients and patients with acute or chronic hepatitis B virus (HBV) infection. Clin Exp Immunol. 1996;105:52–58.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Yu, JW., Sun, LJ., Zhao, YH. et al. The Study of Efficacy of Lamivudine in Patients with Severe Acute Hepatitis B. Dig Dis Sci 55, 775–783 (2010). https://doi.org/10.1007/s10620-009-1060-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10620-009-1060-5